Castration-Resistant Prostate Cancer (CRPC) Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Castration-Resistant Prostate Cancer Treatment Market Size 2024-2028

The castration-resistant prostate cancer treatment market size is forecast to increase by USD 5.98 billion at a CAGR of 8.83% between 2023 and 2028.

• The market is experiencing significant growth due to the increasing prevalence of prostate cancer and the evolution of new treatment options. As prostate cancer advances and becomes resistant to hormone therapy, patients require alternative treatment methods. The market is witnessing the development of new proteins and targeted therapies such as cell and gene therapy, which offer improved efficacy and reduced side effects compared to traditional CRPC treatments. However, the use of these advanced therapies comes with health complications, such as cardiovascular events and bone health issues, which can impact patient quality of life and increase healthcare costs. Therefore, there is a growing need for effective management strategies to mitigate these side effects and improve patient outcomes.
• In summary, the CRPC treatment market is driven by the rising incidence of prostate cancer and the emergence of innovative treatment options and medical technologies, while challenges include managing the side effects of existing therapies and ensuring patient access to affordable and effective care.

What will be the Size of the Castration-Resistant Prostate Cancer Treatment Market During the Forecast Period?

 Request Free Sample

• The market encompasses a range of therapies designed to manage the advanced stage of prostate cancer that is no longer responsive to traditional hormone therapy. This ailment, characterized by the continued production of testosterone despite castration or medical castration, affects a significant portion of prostate cancer patients. The market dynamics are driven by the increasing incidence of CRPC, which is diagnosed through various methods including PSA testing and prostate biopsy. New treatments, including combination therapies, are emerging to address the unmet needs of this patient population. These new treatments include hormone therapy, targeted therapies such as enzalutamide and abiraterone, and testosterone-lowering therapy.
• Regulatory agencies continue to approve these therapies, expanding the treatment landscape for CRPC. Additionally, precision medicine is gaining traction, tailoring therapies to individual patients based on genetic markers. CRPC patients may experience symptoms such as difficulty urinating, weight loss, and shortness of breath, necessitating ongoing healthcare expenditure. The geriatric population, a significant portion of CRPC patients, further complicates treatment approaches due to comorbidities and age-related factors.

How is this CRPC Treatment Industry segmented and which is the largest segment?

The castration-resistant prostate cancer treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Therapy
  • Hormonal therapy
  • Chemotherapy
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Distribution Channel Insights

• The hospital pharmacies segment is estimated to witness significant growth during the forecast period.

The market is characterized by the adoption of various therapies, including hormone therapy, surgical castration, medical castration, and new treatments such as combination therapies. Hormone therapy, which includes testosterone-lowering therapy, remains a conventional option for CRPC treatment. Newer treatments, like second-line hormone therapy, chemotherapy, immunotherapy, radiopharmaceutical therapy, and targeted therapy, are gaining popularity due to their efficacy in managing CRPC resistance mechanisms. Personalized medicine and technological integration are driving innovation in CRPC diagnosis and treatment, with diagnostic tools like imaging technologies, genomic testing, and liquid biopsies playing crucial roles. The European market is witnessing significant growth, with oral route and injectable drug delivery methods dominating the distribution channel landscape.

Hospital pharmacies hold the largest market share due to their role in ensuring patient safety and proper medication administration within healthcare facilities. Key players are focusing on clinical trials to develop more effective and less burdensome treatment options, addressing side effects and improving overall patient outcomes.

Get a glance at the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry report of share of various segments. Request Free Sample

The Hospital pharmacies segment was valued at USD 6.35 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 47% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The North American market for castration-resistant prostate cancer (CRPC) treatment is experiencing steady growth due to the increasing incidence of prostate cancer. Advanced healthcare infrastructure In the region is driving market expansion. In 2022, US healthcare expenditure surpassed USD4.5 trillion, marking a 4% increase from the previous year. This growth in healthcare spending is fueling demand for CRPC therapies. Additionally, the rising number of prostate cancer patients presents opportunities for market participants. Combination therapies, including hormone therapy, testosterone-lowering agents, and surgical or medical castration, remain conventional treatments for CRPC. Newer treatments, such as second-line hormone therapy (abiraterone acetate, an androgen receptor inhibitor), chemotherapy, immunotherapy, radiopharmaceutical therapy, targeted therapy, and clinical trials, are also gaining popularity.

Key diagnostic tools, such as imaging technologies, genomic testing, and liquid biopsies, aid in CRPC diagnosis and treatment selection. Side effects and efficacy, as well as resistance mechanisms, are crucial factors influencing treatment choice. The European market is also witnessing growth, with oral route and injectable drug delivery methods, distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies, and regulatory agencies playing significant roles.

Market Dynamics

Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Castration-Resistant Prostate Cancer (CRPC) Treatment Industry?

Increasing prevalence of prostate cancer is the key driver of the market.

• Prostate cancer is a significant health concern, accounting for over a million deaths annually worldwide. The exact cause of this ailment is unknown, but age and certain risk factors contribute to its development. The global population aged 60 and above is projected to double from 12% to 22% between 2015 and 2050, increasing the prevalence of prostate cancer. Hormone therapy, including surgical castration and medical castration, has been the conventional treatment for prostate cancer. However, with the emergence of resistance mechanisms, new treatments such as combination therapies, second-line hormone therapy, chemotherapy, immunotherapy, radiopharmaceutical therapy, and targeted therapy are being explored.
• These new treatments include androgen receptor inhibitors like Abiraterone acetate and non-steroidal antiandrogens like Enzalutamide. Technological integration In the form of diagnostic tools, imaging technologies, genomic testing, and liquid biopsies is revolutionizing the diagnosis and treatment of CRPC. The market for CRPC treatments is dynamic, with regulatory agencies approving new treatments and therapies continually. The treatment options come with side effects such as difficulty urinating, weight loss, and shortness of breath, particularly In the geriatric population. Healthcare expenditure on CRPC treatments is substantial, with distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies.

What are the market trends shaping the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry?

Evolving CRPC treatment options is the upcoming market trend.

• The market is witnessing significant advancements due to the development of new therapies for patients with elevated PSA levels while undergoing androgen deprivation therapy without visible metastases. The short PSA doubling time In these patients is associated with a reduced time to first metastasis and death. companies are focusing on creating alpha particle-emitting radioactive therapeutic agents for CRPC treatment. For instance, Bayer AG has successfully developed such a treatment, which has gained approval in over 50 countries for its effectiveness in treating CRPC and alleviating symptoms caused by bone metastases. Combination therapies, including hormone therapy, testosterone-lowering therapy, and medical castration, remain conventional treatment options.
• However, the emergence of second-line hormone therapy, chemotherapy, immunotherapy, radiopharmaceutical therapy, and targeted therapy is expanding the treatment landscape. Technological integration of diagnostic tools, such as genomic testing, imaging technologies, and liquid biopsies, is enabling personalized medicine. Side effects and efficacy remain critical factors in CRPC treatment, with resistance and mechanisms of resistance being areas of ongoing research. The European market is a significant contributor to the global CRPC treatment market. The distribution channel includes hospital pharmacies, retail pharmacies, and online pharmacies. Treatment options include oral route and injectable route drug delivery methods. Key treatments include Abiraterone acetate, an androgen receptor inhibitor, and Enzalutamide, an androgen receptor inhibitor and non-steroidal antiandrogen.
• Regulatory agencies play a crucial role in approving new treatments. Side effects, such as difficulty urinating, weight loss, and shortness of breath, are common in CRPC patients. The geriatric population and healthcare expenditure are major factors influencing the market.

What challenges does the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry face during its growth?

Health complications related to CRPC drugs is a key challenge affecting the industry growth.

• Prostate cancer, a common ailment In the oncology sector, can progress into Castration-Resistant Prostate Cancer (CRPC) despite initial hormone therapy and surgical or medical castration. Abiraterone acetate, an androgen receptor inhibitor, is a second-line hormone therapy option for CRPC patients. This medication, in combination with prednisone, is approved for treating metastatic CRPC. Abiraterone works by inhibiting the synthesis of androgens In the adrenal glands. While these therapies offer efficacy in managing CRPC, they come with side effects such as joint swelling or pain, groin pain, hot flashes, diarrhea, constipation, heartburn, cough, difficulty falling asleep or staying asleep, sore throat, and stuffy or runny nose.
• The European market for CRPC treatment is witnessing the integration of technological advancements, including diagnostic tools like genomic testing and imaging technologies, and new treatments such as chemotherapy, immunotherapy, radiopharmaceutical therapy, and targeted therapy. The distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies. Healthcare expenditure for CRPC treatment In the geriatric population is a significant concern due to the side effects and resistance mechanisms of conventional medications like abiraterone and enzalutamide. Clinical trials are ongoing to explore new treatment options and minimize side effects.

Exclusive Customer Landscape

The castration-resistant prostate cancer treatment market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the CRPC treatment market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, castration-resistant prostate cancer (crpc) treatment market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

Active Biotech AB - The company is engaged in the development of treatments for Castration-Resistant Prostate Cancer (CRPC), specifically Tasquinimod (TASQ), which is currently in phase III clinical trials for men diagnosed with metastatic castrate-resistant prostate cancer.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Active Biotech AB
• Allarity Therapeutics Inc.
• Amgen Inc.
• Amneal Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Bayer AG
• BeiGene Ltd.
• Daiichi Sankyo Co. Ltd.
• Dr Reddys Laboratories Ltd.
• Everest Pharmaceuticals Ltd.
• F. Hoffmann La Roche Ltd.
• Johnson and Johnson
• Medias Klinikum GmbH and Co. KG
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Robotic Prostate Centre Cambridge
• Sanofi SA
• The Focal Therapy Clinic
• Ono Pharmaceutical Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Prostate cancer is a significant health concern worldwide, with castration-resistant prostate cancer (CRPC) being a late-stage manifestation of the disease. CRPC is characterized by the continued growth of the tumor despite androgen deprivation therapy (ADT), which includes surgical castration and medical castration. The ailment poses a significant challenge to the healthcare system due to its resistance to conventional hormone therapy and the need for new treatment options. The CRPC market is witnessing substantial growth due to the increasing incidence of the disease and the development of new therapies. The market dynamics are driven by various factors, including the advancement of technology and personalized medicine.

Technological integration In the form of diagnostic tools, imaging technologies, genomic testing, and liquid biopsies is revolutionizing the diagnosis and treatment of CRPC. Personalized medicine plays a crucial role In the CRPC treatment landscape. The use of genomic testing and liquid biopsies enables the identification of specific biomarkers, leading to targeted therapies tailored to individual patients. New treatments, such as second-line hormone therapy, chemotherapy, immunotherapy, radiopharmaceutical therapy, and targeted therapy, are under development and show promising results. Clinical trials are ongoing to evaluate the efficacy and side effects of these new treatments. The side effects of CRPC treatments, including difficulty urinating, weight loss, and shortness of breath, are significant concerns for the geriatric population.

Healthcare expenditure on CRPC treatment is expected to increase as the population ages and new treatments become available. The CRPC market is segmented based on therapy type, route of administration, and distribution channel. Hormone therapy, including androgen receptor inhibitors, remains a significant portion of the market. Abiraterone acetate and enzalutamide are notable examples of androgen receptor inhibitors. The market also includes non-steroidal antiandrogens, corticosteroids, microtubule inhibitors, and other antineoplastic agents. The route of administration for CRPC treatments includes oral and injectable. Oral route medications offer convenience and improved patient compliance, while injectable treatments provide more rapid onset of action.

The distribution channel for CRPC treatments includes hospital pharmacies, retail pharmacies, and online pharmacies. Regulatory agencies play a crucial role In the CRPC treatment market, ensuring the safety and efficacy of new treatments. The regulatory approval process for new treatments is lengthy and complex, but it is essential to ensure that patients have access to safe and effective treatments. In conclusion, the CRPC treatment market is dynamic and complex, driven by the need for new treatments and the advancement of technology. The market is segmented based on therapy type, route of administration, and distribution channel. The use of personalized medicine and targeted therapies is revolutionizing the treatment landscape, offering new hope for patients. The challenges of CRPC, including resistance mechanisms and side effects, remain significant, but ongoing research and development hold promise for the future.

Request Free Sample

What are the Key Data Covered in this Castration-Resistant Prostate Cancer Treatment Market Research and Growth Report?

• CAGR of the Castration-Resistant Prostate Cancer (CRPC) Treatment industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the castration-resistant prostate cancer (crpc) treatment market growth of industry companies

We can help! Our analysts can customize this CRPC treatment market research report to meet your requirements.

Get in touch